Skip to content

Combined Pharmacotherapies for Alcoholism

Combined Pharmacotherapies for Alcoholism

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00768508
Enrollment
300
Registered
2008-10-08
Start date
2008-09-30
Completion date
2012-12-31
Last updated
2013-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholism

Keywords

Alcohol, Alcohol Dependence, Alcoholism

Brief summary

This study would like to test whether the combination of ondansetron and naltrexone will be superior to either medication alone or placebo in the treatment of alcohol dependence.

Detailed description

We propose to conduct a 13 week randomized, controlled clinical trial to evaluate the safety and efficacy of ondansetron and naltrexone alone and in combination.Eligible subjects will be randomized to placebo, ondansetron, naltrexone, or ondansetron + naltrexone treatments. All subjects will receive a weekly CBT (Cognitive Behavioral Therapy)sessions.

Interventions

DRUGOndansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy

Ondansetron 4 ug/kg b.i.d.for 12 weeks

DRUGNaltrexone 50 mg/day + Cognitive Behavioral Therapy

Naltrexone 50 mg/day for 12 weeks

DRUGOndansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy

Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
Bankole Johnson
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Males and females who have given written informed consent. * Ages 18 years and above and must weigh at least 40 kg and no more than 140 kg. * Good physical health as determined by a complete physical examination, an EKG within normal limits, and laboratory screening tests within acceptable parameters (see

Exclusion criteria

). * Current DSM-IV diagnosis of alcohol dependence * AUDIT score of equal or more than 8. * Currently drinking * Provide evidence of stable residence in the last month prior to enrollment in the study, and have no plans to move in the next three months. * The pregnancy test for females at intake must be negative. Additionally, women of childbearing potential must be using an acceptable form of contraception. These include: oral contraceptives, hormonal (levonorgestrel) or surgical implants, or barrier plus spermicide. * Literate in English and able to read, understand, and complete the ratings scales and questionnaires accurately, follow instructions, and make use of the behavioral treatments. * Answer an advertisement in the newspaper/radio/television, or be referred from a health care professional and express a wish to stop drinking. * Willingness to participate in behavioral treatments for alcoholism.

Design outcomes

Primary

MeasureTime frameDescription
Self-report measures of alcohol-related problems and consumption, Objective measures of alcohol consumptionThroughout the studyDrinks per drinking day, Drinks per day, Percent Days Abstinent, BAC, CDT, GGT

Secondary

MeasureTime frameDescription
Medication compliance, alcohol craving, social functioning, quality of life, alcohol withdrawal, attendance at psychosocial services, pre-morbid risk factorsThroughout the studyPill Count, SFQ, AASE, ADBS, OCDS, CIWA-Ar, CGI, TCI, MAC, AOQ, FHAM

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026